ERYTECH announces positive safety review for eryaspase in its Phase 2 study in pancreatic cancer Post author:admERY Post published:July 20, 2015 Post category:Newsroom ERYTECH announces a positive DSMB safety review following the treatment of the first twenty-four patients with eryaspase in its Phase 2 study in pancreatic cancer. You Might Also Like ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014 ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020 ERYTECH to Present at the 2021 BIO CEO & Investor Conference February 10, 2021
ERYTECH to report positive initial results on the use of GRASPA® in ALL patients allergic to E. Coli and Erwinia derived asparaginases at ASH November 7, 2014
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2020 September 21, 2020